Early referral and comorbidity as possible causes of the declining transition rate in subjects at clinical high risk for psychosis

Early Intervention in Psychiatry

Volumn 12, Issue 4, 2018, Pages 596-604

  Lim, Kyung Ok ^a   Lee, Tae Young ^a   Kim, Minah ^b   Chon, Myong Wuk ^b   Yun, Je Yeon ^b   Kim, Sung Nyun ^b   Kwon, Jun Soo ^b,c,d  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

comorbidity; prodromal symptoms; psychosis; referral.

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; OLANZAPINE;

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DRUG USE; FEMALE; FUNCTIONAL ASSESSMENT; GLOBAL ASSESSMENT FUNCTION SCALE; HIGH RISK PATIENT; HUMAN; INTELLIGENCE QUOTIENT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE ASSESSMENT; NEGATIVE SYNDROME; PATIENT REFERRAL; PRIORITY JOURNAL; PRODROMAL SYMPTOM; PSYCHOSIS; RISK ASSESSMENT; RISK FACTOR; SCALE OF PRODROMAL SYMPTOM; SCHIZOTYPAL PERSONALITY DISORDER; TRANSITIONAL CARE; YOUNG ADULT; COMPARATIVE STUDY; DISEASE EXACERBATION; MENTAL DISEASE; PSYCHOLOGICAL RATING SCALE; SOUTH KOREA;

COMORBIDITY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MENTAL DISORDERS; PRODROMAL SYMPTOMS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; REFERRAL AND CONSULTATION; REPUBLIC OF KOREA; RISK FACTORS; YOUNG ADULT;

EID: 84992597911     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/eip.12363     Document Type: Article

References (38)

1. Gaudiano BA, Zimmerman M. Prevalence of attenuated psychotic symptoms and their relationship with DSM-IV diagnoses in a general psychiatric outpatient clinic. J Clin Psychiatry 2013; 74: 149–55
2. Yung AR, Yuen HP, Berger G et al. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophr Bull 2007; 33: 673–81
3. Simon AE, Borgwardt S, Riecher-Rossler A, Velthorst E, de Haan L, Fusar-Poli P. Moving beyond transition outcomes: meta-analysis of remission rates in individuals at high clinical risk for psychosis. Psychiatry Res 2013; 209: 266–72
4. Fusar-Poli P, Bonoldi I, Yung AR et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 2012; 69: 220–9
5. Wiltink S, Velthorst E, Nelson B, McGorry PM, Yung AR. Declining transition rates to psychosis: the contribution of potential changes in referral pathways to an ultra-high-risk service. Early Interv Psychiatry 2013; 9: 200–6
6. Chon MW, Lee TY, Kim SN et al. Factors contributing to the duration of untreated prodromal positive symptoms in individuals at ultra-high risk for psychosis. Schizophr Res 2015; 162: 64–6
7. Lim J, Rekhi G, Rapisarda A et al. Impact of psychiatric comorbidity in individuals at ultra high risk of psychosis: findings from the Longitudinal Youth at Risk Study (LYRIKS). Schizophr Res 2015; 164: 8–14
8. Fusar-Poli P, Nelson B, Valmaggia L, Yung AR, McGuire PK. Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis. Schizophr Bull 2014; 40: 120–31
9. Salokangas RK, Ruhrmann S, von Reventlow HG et al. Axis I diagnoses and transition to psychosis in clinical high-risk patients EPOS project: prospective follow-up of 245 clinical high-risk outpatients in four countries. Schizophr Res 2012; 138: 192–7
10. Nelson B, Yuen HP, Wood SJ et al. Long-term follow-up of a group at ultra high risk ("prodromal") for psychosis: the PACE 400 study. JAMA Psychiatry 2013; 70: 793–802
11. Ruhrmann S, Schultze-Lutter F, Salokangas RK et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry 2010; 67: 241–51
12. Cannon TD, Cadenhead K, Cornblatt B et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008; 65: 28–37
13. Schmidt SJ, Schultze-Lutter F, Schimmelmann BG et al. EPA guidance on the early intervention in clinical high risk states of psychoses. Eur Psychiatry 2015; 30: 388–404
14. Van der Gaag M, Smit F, Bechdolf A et al. Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr Res 2013; 149: 56–62
15. McGorry PD, Nelson B, Phillips LJ et al. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. J Clin Psychiatry 2013; 74: 349–56
16. McGlashan TH, Zipursky RB, Perkins D et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163: 790–9
17. Yung AR, Phillips LJ, Nelson B et al. Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis. J Clin Psychiatry 2011; 72: 430–40
18. Fleischhacker WW, Simma AM. Managing the prodrome of schizophrenia. In: Gross G, Geyer MA, eds Current Antipsychotics Handbook of Experimental Pharmacology. New York: Springer, 2012, 125–34
19. Lee TY, Kim SN, Correll CU et al. Symptomatic and functional remission of subjects at clinical high risk for psychosis: a 2-year naturalistic observational study. Schizophr Res 2014; 156: 266–71
20. Kwon JS, Byun MS, Lee TY, An SK. Early intervention in psychosis: Insights from Korea. Asian J Psychiatr 2012; 5: 98–105
21. Yum T, Park Y, Oh K, Kim J, Lee Y. The Manual of Korean-Wechsler Adult Intelligence Scale. Korea Guidance: Seoul, 1992
22. Miller TJ, McGlashan TH, Rosen JL et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry 2002; 159: 863–5
23. Jung MH, Jang JH, Kang DH et al. The reliability and validity of the Korean version of the structured interview for prodromal syndrome. Psychiatry Invest 2010; 7: 257–63
24. Hall RC. Global assessment of functioning: a modified scale. Psychosomatics 1995; 36: 267–75
25. Ventura J, Lukoff D, Nuechterlein KH, Liberman RP, Green MF, Shaner A. Brief Psychiatric Rating Scale (BPRS) expanded version: scales, anchor points, and administration manual. Int J Methods Psychiatr Res 1993; 3: 227–43
26. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62
27. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50–5
28. First MB, Spitzer RL, Gibbon M, Williams JB. Structured clinical interview for Axis I DSM-IV disorders. New York: Biometrics Research, 1994
29. First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS. Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). Washington, DC: American Psychiatric Press, Inc., 1997
30. Lin A, Wood SJ, Nelson B, Beavan A, McGorry P, Yung AR. Outcomes of nontransitioned cases in a sample at ultra-high risk for psychosis. Am J Psychiatry 2015; 172: 249–58
31. Nelson B, Yuen K, Yung AR. Ultra high risk (UHR) for psychosis criteria: are there different levels of risk for transition to psychosis? Schizophr Res 2011; 125: 62–8
32. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry 2010; 167: 686–93
33. Yang J, Bahk WM, Cho HS et al. Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial. Clin Neuropharmacol 2010; 33: 169–75
34. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 2010; 67: 255–62
35. Kim E, Jang JH, Park HY et al. Pharmacotherapy and clinical characteristics of ultra-high-risk for psychosis according to conversion status: a naturalistic observational study. Early Interv Psychiatry 2012; 6: 30–7
36. Velthorst E, Nelson B, Wiltink S et al. Transition to first episode psychosis in ultra high risk populations: does baseline functioning hold the key? Schizophr Res 2013; 143: 132–7
37. Hutton P, Taylor PJ. Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysis. Psychol Med 2014; 44: 449–68
38. Marvin SE, Miklowitz DJ, O'Brien MP, Cannon TD. Family-focused therapy for individuals at clinical high risk for psychosis: treatment fidelity within a multisite randomized trial. Early Interv Psychiatry 2014; 10: 137–43